Enables Broad Commercialization of Highly Specific Engineered
RESEARCH TRIANGLE PARK, N.C. & PARIS--(BUSINESS WIRE)--
Precision BioSciences, Inc. and Cellectis SA (Paris:ALCLS), today
announced that they have reached an agreement to settle patent
litigation involving engineered I-CreI meganuclease technology. As part
of the settlement, the companies will cross-license certain genome
engineering patents and drop their on-going lawsuits and patent
challenges. This agreement provides clear freedom to operate for both
companies in the engineered I-CreI meganuclease genome engineering field.
Engineered meganucleases are one of the preferred genome engineering
technologies for most high-value applications. Their small size and
exquisite specificity make them safer and easier to deliver than
alternative gene editing tools. In addition, current embodiments of the
technology are versatile enough to edit any gene in a genome.
“We are pleased to have reached this agreement with our colleagues at
Cellectis,” said Matthew Kane, Precision BioSciences’ CEO, “and are very
much looking forward to focusing fully on the commercial development of
highly needed products utilizing our Directed Nuclease Editor
genome engineering technology.”
“This agreement with our colleagues at Precision Biosciences sets the
value of innovation of a proven and effective genome engineering tool:
meganucleases,” stated Dr. AndrÉ Choulika, Chairman and CEO of
Cellectis, “This natural technology has tremendous advantages and has
now the full potential to be developed in a number important
applications such as agricultural biology and bioproduction.”
About Precision BioSciences
Precision BioSciences’ mission is to continually provide, improve, and
enable the world’s most powerful genome engineering technology.
Precision’s proprietary Directed Nuclease EditorTM
(DNE) technology enables the production of genome editing enzymes that
can insert, remove, modify, and regulate essentially any gene in
mammalian or plant cells.
Precision BioSciences’ vision is to be the conduit through which the
world’s greatest genome engineering challenges are solved. Precision has
successfully utilized its DNE technology to create innovative products
in partnerships with many of the world’s largest biopharmaceutical and
agbiotech firms. Internally, Precision is developing DNE-based products
for biologics manufacturing and human therapeutics. For additional
information, please visit www.precisionbiosciences.com.
Cellectis is a biopharmaceutical company focused on oncology. The
company’s mission is to develop a novel generation of therapy based on
allogeneic T-cell to treat cancer. Cellectis capitalizes on its 14 years
of expertise in genome engineering based on TALEN™, meganuclease, and,
the state-of-the-art electroporation technology Pulsagile to create the 4th
generation of cancer immunotherapy to treat leukemia and solid tumors.
Cellectis adoptive cancer immunotherapy to cure chronic and acute
leukemias is based on the first allogeneic T-cell Chimeric Antigen
Receptor (CAR) technology. CAR technologies are designed to target cell
surface antigens expressed on cells. These treatments reduce toxicities
associated with current chemotherapeutics and have the potential for
curative therapy. The Cellectis Group is focused on life sciences and
use leading genome engineering technologies to build innovative products
in various fields and markets. Cellectis is listed on the NYSE Alternext
market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country.
Philippe Valachs, +33 (0)1 81 69 16 00
Chelsea Lynam, +1 919 314-5512
Source: Cellectis SA